Monday, May 12, 2025 – This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in…
Sunday, May 11, 2025 – The common belief is that as GLP-1s become more popular, that will stimulate competition in generics and new drug development. This is all good, right? However, this has not always been true. This news article…
Sunday, May 11, 2025 – Several companies and research groups are actively exploring implantable drug delivery systems for GLP-1 receptor agonists (GLP-1 RAs), aiming to improve patient adherence, convenience, and therapeutic outcomes. Here’s a summary of key players and motivations:…
Friday, May 9, 2025 – March 14, 2025 Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the…
Thursday, May 8, 2025 – Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan…
Thursday, May 8, 2025 – January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large,…
Wednesday, May 7, 2025 – Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended for weight reduction and maintenance in both adult and pediatric patients with obesity or…
Sunday, May 4, 2025 – by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038 Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies,…
Saturday, May 3, 2025 – The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications.…
Thursday, May 1, 2025 – That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm Researchers in Dallas are investigating the potential of weight loss medications,…